Ads
related to: multiple myeloma- How Treatment Works
Watch a Short Video About
How This Treatment Works
- Treatment Schedule
Learn How This Treatment Is Given
See the Infusion Schedule
- Resources
Download Helpful Resources
for Patients and Caregivers
- Phase 3 Trials
See Study Results
From the Latest Trial
- Safety Information
Read Safety Information
for Patients and Caregivers
- Patient Support Program
Eligible Patients May Qualify
for Financial Assistance
- How Treatment Works
Search results
Adaptive Biotechnologies Expects Growth From FDA Panel MRD Vote, Cuts Staff by 7 Percent in Q1
GenomeWeb News· 20 hours agoThe Seattle-based immune sequencing firm also shed light on its strategic review that will separate its MRD and immune medicine businesses, disclosing that it reduced its headcount by almost ...
...Economic Model Data for APHEXDA® (motixafortide) as part of CD34+ Hematopoietic Stem Cell...
WTNH-TV New Haven· 3 days ago...commercial stage biopharmaceutical company pursuing life-changing therapies in oncology and rare...
Karyopharm Therapeutics Inc (KPTI) Q1 2024 Earnings Call Transcript Highlights: Navigating ...
GuruFocus.com via Yahoo Finance· 3 hours agoPromising data from ongoing trials in multiple myeloma, endometrial cancer, and myelofibrosis suggest potential for significant patient benefits and market ...
Elrexfio and dosage: Strengths, form, when to use, and more
Medical News Today· 3 days agoElrexfio (elranatamab-bcmm) is a brand-name drug that’s prescribed for specific cases of multiple ...
Personalis Inc (PSNL) (Q1 2024) Earnings Call Transcript Highlights: Surpassing Revenue ...
GuruFocus.com via Yahoo Finance· 2 hours agoWe also anticipate New York approval for both tests, positioning us well within the regulatory framework. Q: Following the recent AdCom meeting on MRD as an endpoint in multiple< ...
2seventy bio Inc (TSVT) Q1 2024 Earnings Call Transcript Highlights: Strategic Shifts and ...
GuruFocus.com via Yahoo Finance· 3 hours agoDespite strategic realignment, the company had to implement a headcount reduction by an additional 14%, which could impact morale and operational capacity. The market for multiple< ...
Earnings call: Genmab reports strong Q1 growth, plans ProfoundBio acquisition By Investing.com
Investing.com· 6 days agoGenmab A/S (NASDAQ:GMAB), the Danish biotechnology company, reported robust financial results in its...
Earnings call: Adaptive Biotechnologies reports robust MRD growth By Investing.com
Investing.com· 2 hours agoAdaptive Biotechnologies (NASDAQ:ADPT) has announced its financial results for the first quarter of...
Karyopharm Reports First Quarter 2024 Financial Results and Highlights Recent Company Progress
NBC 17 Raleigh· 23 hours ago– Announces Significant Refinancing Transactions and Amends Royalty Agreement with HealthCare Royalty Extending Vast Majority of Its Debt Maturities into 2028 and 2029, Well Beyond Expected ...
Adaptive Biotechnologies Corp (ADPT) Q1 2024 Earnings Call Transcript Highlights: Strategic ...
GuruFocus.com via Yahoo Finance· 1 day agoThe FDA's Oncologic Drugs Advisory Committee recommended MRD as a primary endpoint for accelerated approval of new therapies for multiple myeloma, potentially ...
Ads
related to: multiple myeloma
